Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy

Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of ...
TMCnet

Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis

The Phase 2 MoonStone trial, which enrolled 116 patients ... The primary endpoint is the cumulative number of new Gd-enhancing T1 hyperintense lesions over week 8 and week 12 as measured by brain MRI.
Fierce Biotech

Zenas' autoimmune drug prompts 95% reduction in new brain lesions in phase 2 MS study

Zenas Biopharma’s lead autoimmune drug has been tied to a 95% reduction in a type of brain lesions over 12 weeks in a phase 2 multiple sclerosis (MS) study.  | Zenas Biopharma’s lead autoimmune drug ...
TipRanks on MSN

Takeda presents interim data from Phase 1b study of mezagitamab

Takeda (TAK) announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab, an anti-CD38 monoclonal ...
Purdue University

Eradivir announces Phase 2 human challenge study of EV25 in healthy adults infected with influenza

WEST LAFAYETTE, Ind. — Eradivir, a clinical-stage small molecule immunotherapy biotech company, announced it has begun a Phase 2 challenge study with its antiviral therapeutic, EV25. The study will ...